FONDATION IMAGINE
Patent Owner
Stats
- 3 US PATENTS IN FORCE
- 3 US APPLICATIONS PENDING
- Feb 01, 2018 most recent publication
Details
- 3 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 4 Total Citation Count
- Apr 10, 2013 Earliest Filing
- 4 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Intl Class
Technology
Matters
Rank in Class
Top Patents (by citation)
Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
Publication #
Title
Filing Date
Pub Date
Intl Class
2018/0031,579 METHODS FOR PREDICTING THE RESPONSIVENESS OF A PATIENT AFFECTED WITH MALIGNANT HEMATOLOGICAL DISEASE TO CHEMOTHERAPY TREATMENT AND METHODS OF TREATMENT OF SUCH DISEASEFeb 11, 16Feb 01, 18[A61K, G01N, C07K]
2017/0051,062 Methods and Pharmaceutical Compositions for the Treatment of Diseases Mediated by the NRP-1/OBR Complex Signaling PathwayFeb 18, 15Feb 23, 17[A61K, C12N, G01N, C07K]
2017/0020,847 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF BETA-THALASSEMIASNov 18, 14Jan 26, 17[A61K, G01N]
Recent Patents
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
2016/0368,975 METHODS AND COMPOSITIONS FOR THE TREATMENT OF BETA-THALASSEMIAAbandonedMay 23, 16Dec 22, 16[A61K, G01N, C07K]
2016/0051,674 METHODS AND PHARMACEUTICAL COMPOSITIONS (CTPS 1 INHIBITORS, E.G. NORLEUCINE) FOR INHIBITING T CELL PROLIFERATION IN A SUBJECT IN NEED THEREOFAbandonedApr 17, 14Feb 25, 16[A61K, G01N]
2015/0197,574 USE OF TRANSFERRIN RECEPTOR ANTAGONIST FOR THE TREATMENT OF THALASSEMIAAbandonedAug 02, 13Jul 16, 15[C07K]
Top Inventors for This Owner
Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.